Metformin

• A geroscience approach to post-acute COVID-19 syndrome (PACS) by Diet and Exercise plus rapamycin or metformin to treat Frailty and restore … Not authorised
  2023-504641-32-00 Phase II 1 country Azienda Ospedaliero Universitaria Di Modena
• RECLAIM: an Adaptive Platform Trial for the Evaluation of Treatments for Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Not authorised
  2024-511580-28-00 Phase III 1 country Universitair Medisch Centrum Utrecht
• Optimizing metformin use in polycystic ovary syndrome - A randomized controlled trial Pending
  2023-509259-15-01 Phase IV 1 country HUS-yhtymae
• "MetCool ACS"- Metformin "Cooling" Effect on metformin-naive Patients Treated with PCI because of Acute Coronary Syndrome Pending
  2024-516589-13-00 Phase III 1 country Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
• A Study of Tirzepatide Compared with Intensified Conventional Care in Adult Participants with Type 2 Diabetes (SURPASS-EARLY) Recruiting
  2022-501073-40-00 Phase IV 5 countries Eli Lilly & Co.
• Metformin for cancer prevention in Li-Fraumeni Syndrome (LFS) Recruiting
  2025-520714-63-00 Phase III 1 country Medizinische Hochschule Hannover
• RECLAIM: an Adaptive Platform Trial for the Evaluation of Treatments for Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Recruiting
  2024-511580-28-02 Phase III 1 country Universitair Medisch Centrum Utrecht
• Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi-centre, 2 par… Recruiting
  2024-517864-49-01 Phase III 1 country University Of Bari Aldo Moro
• A Study to Evaluate Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC) Recruiting
  2023-503629-20-00 Phase I/II 3 countries F. Hoffmann-La Roche AG
• A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokine… Ended
  2023-504215-32-00 Phase I/II 3 countries AstraZeneca AB
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Recepto… Ended
  2022-502322-41-00 Phase III 6 countries F. Hoffmann-La Roche AG
• A study to evaluate the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin wit… Ended
  2024-511408-18-00 Phase III 5 countries Institut De Recherches Internationales Servier IRIS
• A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W… Ended
  2023-507206-13-00 Phase III 2 countries Eli Lilly & Co.
• Transfer of metformin into human breast milk and the plasma of breastfeeding children - A low intervention trial with biobanking of breast m… Ended
  2022-501693-19-00 Phase IV 1 country Uppsala Universitet
• A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or With… Ended
  2023-507280-18-00 Phase III 1 country Eli Lilly & Co.
• A research study to see how well new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar… Ended
  2022-502484-38-00 Phase III 3 countries Novo Nordisk A/S
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight… Ended
  2022-502678-18-00 Phase III 15 countries Novo Nordisk A/S
• A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase… Ended
  2022-502833-25-00 Phase III 8 countries Eli Lilly & Co.
• A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended
  2022-500101-41-00 Phase IV 4 countries Eli Lilly Cork Limited

Showing 1–19 of 19 trials